ブランドジェネリック市場：製品タイプ、薬剤タイプ、投与経路、適応症、流通チャネル別-2024～2030年の世界予測

ブランドジェネリック市場規模は、2023年に4,323億米ドルと推定され、2024年には4,942億9,000万米ドルに達し、CAGR 14.66％で2030年には1兆1,264億3,000万米ドルに達すると予測されます。

ブランドジェネリック医薬品とは、先発医薬品と生物学的に同等な医薬品を指し、特許満了後に他社から別のブランド名で販売されます。これらの医薬品は、先発医薬品と同じ有効成分（API）を使用して製剤化され、製造工程、安全性プロファイル、有効性基準に関する同様の規制要件を満たさなければならないです。しかし、ブランドジェネリックは、賦形剤、包装材料、製造技術などの点で、新薬と比較して微妙な違いを示すことがあります。利用しやすい治療法に関する消費者の意識の高まり、医療費の増加、ブロックバスター医薬品の特許切れの増加が、ブランドジェネリック市場の成長を後押ししています。しかし、医薬品の承認や品質管理に関する厳しい規制要件や、メーカー間の熾烈な競争による価格下落は、市場の成長を阻害する可能性があります。とはいえ、生物学的に同等な製品の開発を可能にする医薬品研究の進歩は、ブランドジェネリック市場の成長に有利な機会を生み出します。

製品付加価値の高いブランドジェネリックは、その付加的な優位性により大幅な採用が進む

トレードネーム・ジェネリックは、確立されたジェネリック医薬品の信頼できる有効性と、よく知られたブランド名の認知度と評判を組み合わせた医薬品です。これらの製品は、ジェネリック医薬品とブランド医薬品の両方の利点を備え、手頃な価格で高品質です。製薬メーカーは一般的に、競争市場に参入するために商品名のついたジェネリック医薬品を使用し、安全性、有効性、信頼性の信頼を維持しつつ、費用対効果の高い代替品を患者や医療従事者に提供しています。付加価値製品は、消費者にその他の特典をもたらすことで、標準的な製剤とは一線を画すカテゴリーです。これらの付加価値製品は、治療効果を高めるために複数の有効成分を配合したり、徐放性製剤や飲みやすい錠剤など、利便性を向上させるために革新的な剤形を採用したりすることがあります。場合によっては、付加価値のある商品名のジェネリック医薬品には、ベニテックA（オルメサトランとアムロジピンの配合剤）、ニフェディカル（ニフェジピン）、デジテック（ジゴキシン）など、副作用の軽減や患者の服薬アドヒアランス向上のために改良された医薬品も含まれます。

薬剤の種類高血圧治療における降圧剤の高い使用量

アルキル化剤は、主にがん治療に使用される薬剤のクラス別で、DNA複製を阻害することにより、シクロホスファミド、メルファラン、シスプラチンなど、がん細胞の成長と増殖を制限する作用を持っています。抗うつ薬は、脳内の神経伝達物質、特にセロトニン、ノルエピネフリン、ドーパミンのバランスを回復させるため、様々な形態のうつ病や不安障害の治療に使用され、一般的に処方される抗うつ薬にはフルオキセチン、ベンラファキシン、アミトリプチリンなどがあります。抗てんかん薬（AED）は、てんかんと診断された人のてんかん発作を予防または制御するための薬です。降圧薬は、高血圧患者の血圧を下げ、心臓病、脳卒中、その他の合併症のリスクを軽減します。抗精神病薬は、主に双極性障害や統合失調症などの精神病性疾患の症状を管理するために使用されます。代謝拮抗薬は一群の化学療法剤で、がん細胞の細胞代謝やDNA合成を阻害する一方、DNA複製に不可欠なビルディングブロックを模倣したり、これらの過程に関与する重要な酵素を阻害したりします。ホルモン系薬剤は、ホルモンの不均衡、内分泌障害、特定のがんなど、様々な病状に使用されます。脂質低下薬は、血液中のトリグリセリドやコレステロールの上昇を抑え、心臓発作などの心血管障害の可能性を低下させるように設計されています。

投与経路：作用時間が長いため経口投与が広く採用されています。

経口経路は、その利便性、使いやすさ、非侵襲性から、最も一般的で好まれる薬剤投与方法です。錠剤、カプセル剤、液剤などの形態のブランドジェネリック医薬品は、患者が経口で服用します。さらに、投与に特別な器具やヘルスケア専門家の監視が必要ないため、患者のコンプライアンスも向上します。非経口投与では、消化器系をバイパスする手段を用いて、薬物を血流に直接送り込みます。この経路には、皮下（SC）、筋肉内（IM）、静脈内（IV）の注射や輸液が含まれます。この経路は、迅速な緩和が必要な病態の治療や、経口での生物学的利用能が低い薬剤の治療に特に有益です。さらに、特殊な設備や無菌調製が必要なため、一般的に経口投与よりも高価です。局所投与では、クリーム、ゲル、軟膏、経皮パッチなど、ブランドジェネリック医薬品を皮膚や粘膜表面に直接塗布します。このルートでは、全身への吸収や潜在的な副作用を最小限に抑えながら、標的部位に局所的にドラッグデリバリーを行うことができます。局所投与の利点としては、全身投与に比べ副作用のリスクが軽減されること、使いやすいため患者のコンプライアンスが向上することなどが挙げられます。しかしながら、局所ドラッグデリバリーに関連する課題として、皮膚バリアを介した薬物浸透のばらつきや適用部位における刺激の可能性などが挙げられます。

適応症消化器疾患および神経疾患におけるブランドジェネリックの利用急増

ブランドジェネリックは、鎮痛剤、非ステロイド性抗炎症剤（NSAIDs）、オピオイドの選択肢を提供する上で非常に重要です。ブランドジェネリックは、高血圧、高脂血症、心不全、不整脈の管理などの心血管疾患に対して、費用対効果の高い選択肢を提供します。にきび、真菌感染症、湿疹、乾癬などの皮膚疾患は、世界中の患者の間で広く懸念されています。ブランドジェネリックは、コルチコステロイド、レチノイド、抗真菌剤などの皮膚科治療への手頃なアクセスを提供します。炎症性腸疾患（IBD）、胃食道逆流症（GERD）、過敏性腸症候群（IBS）などの消化器疾患は、プロトンポンプ阻害薬（PPI）、H2受容体拮抗薬、鎮痙薬など、費用対効果の高い治療薬を提供するブランドジェネリックによって満たされる薬による長期管理が必要です。てんかん、パーキンソン病、多発性硬化症、片頭痛などの神経疾患では、手頃な価格で効果的な治療が求められており、ブランドジェネリックは抗てんかん薬（AED）、ドーパミン作動薬、モノクローナル抗体などでこのギャップを埋めるお手伝いをしています。ブランドジェネリックは、化学療法薬、ホルモン療法薬、免疫療法薬、チロシンキナーゼ阻害剤（TKI）など、革新的な治療薬や分子標的治療薬には高額な費用がかかるため、実現不可能と思われているがん治療のための費用対効果の高い代替薬を提供しています。Celebrex（セレコキシブ）カプセル、Vascepa（イコサペントエチル）カプセル、Jublia（エフィナコナゾール）外用液、Asacol HD（メサラミン）錠剤、Abraxane（ナブパクリタキセル）、Ampyra（ダルファムプリジン）徐放錠剤のジェネリック医薬品は、いくつかの疾患の治療に利用できます。

販売チャネル進化するブランドジェネリックのオンライン販売チャネル

ブランドジェネリックのオフライン流通チャネルは、主にアクセスのしやすさと医療専門家とのリアルタイムの相談により、薬を求める患者にとって依然として第一の選択肢です。病院薬局は、患者が治療中に手頃な価格で薬を入手できるようにすることで、質の高いヘルスケアを提供する上で重要な役割を果たしています。病院薬局では、手頃な価格と品質保証のバランスが取れたブランドジェネリックがますます好まれています。これらの医薬品は、厳格なガイドラインに従って製造され、特許を取得している医薬品と同等の高い有効性を維持しています。小売薬局は、一般消費者が医薬品を購入する主要な場所であり、品質や効能に妥協することなく、費用対効果の高い代替品を求める消費者のために、ブランドジェネリックに大きな可能性をもたらしています。デジタル技術の急速な進歩は、オンライン薬局やeコマースプラットフォームが医薬品流通の重要なプレーヤーとして台頭する道を開きました。ブランドジェネリックは、詳細な製品情報、競合価格、信頼性の高い配送サービスなど、オンラインチャネルが提供する利便性とコスト削減により、消費者がオンラインで医薬品を購入することを好むようになり、この分野で大きな成長を遂げています。

地域別インサイト

南北アメリカ地域では、強固なヘルスケアインフラと一人当たりの医薬品支出額の高さにより、市場情勢は有利です。ジェネリック医薬品に対する認知度を高めるための政府の取り組みが、ブランドジェネリックの有望な成長見通しにつながっています。さらに、大手製薬企業による研究開発への投資により、新製品が承認され、革新的な治療薬がこの市場に参入しています。欧州連合（EU）は、ブランドジェネリック分野で多様な状況を示しています。EU諸国全体でヘルスケア支出が増加し、各国政府によるジェネリック医薬品に対する有利な価格設定政策が実施される中、費用対効果の高い治療オプションに対する需要がかなり高まっています。大手企業は、新興国市場の低価格医薬品との競争力を維持しつつ、新薬開発のための研究開発に多額の投資を行っています。中東とアフリカは、ヘルスケア・インフラの改善と医薬品の低価格化を目指す政府の取り組みが市場機会の拡大に寄与する原動力となっているため、ブランドジェネリック市場の成長機会として注目されます。アジア太平洋は、研究開発の活発化、政府の支援策、ジェネリック医薬品の需要増加、世界のニーズに対応する革新的な治療法を開発するための国際的な企業間の協力の急増により、ブランドジェネリック開発の大きな可能性を示しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、ブランドジェネリック市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、ブランドジェネリック市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.ブランドジェネリック市場の市場規模および予測は？

2.ブランドジェネリック市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.ブランドジェネリック市場の技術動向と規制枠組みは？

4.ブランドジェネリック市場における主要ベンダーの市場シェアは？

5.ブランドジェネリック市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ジェネリック医薬品の使用を必要とする慢性疾患の蔓延
    • ブロックバスター医薬品の特許切れの増加と費用対効果の高い代替品の必要性
  • 抑制要因
    • ブランドジェネリック医薬品の品質のばらつきに関する懸念
  • 機会
    • 新たな生物学的同等性研究と市場プレーヤーによるブランドジェネリック事業拡大への取り組み
  • 課題
    • 訴訟問題および先発医薬品の価格下落に関する問題
• 市場セグメンテーション分析
  • 製品：付加価値のあるブランドジェネリックの大幅な採用により、追加の利点がもたらされる
  • 薬剤の種類：高血圧の治療に降圧剤を多用する
  • 投与経路：作用持続時間が長いため経口投与が広く採用されている
  • 適応症：消化器疾患および神経疾患におけるブランドジェネリックの利用が急増
  • 配信チャネル：ブランドジェネリックのオンライン配信チャネルの進化
• 市場動向分析
  • 南北アメリカにおけるブランドジェネリックの適切に構造化された標準の利用可能性
  • アジア太平洋地域における政府の支援策と手頃な価格のブランドジェネリック医薬品の需要の高まり
  • EMEA地域におけるブランドジェネリックの地理的範囲の拡大に重点を置く、定評のある製薬会社の存在
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 ブランドジェネリック市場：製品別

• 商品名ジェネリック医薬品
• 付加価値

第7章 ブランドジェネリック市場薬の種類別

• アルキル化剤
• 抗うつ薬
• 抗てんかん薬
• 降圧剤
• 抗精神病薬
• 代謝拮抗物質
• ホルモン
• 脂質低下薬

第8章 ブランドジェネリック市場：投与経路別

• オーラル
• 非経口
• 話題

第9章 ブランドジェネリック市場適応症別

• 急性および慢性疼痛
• 心血管疾患
• 皮膚疾患
• 消化器疾患
• 神経疾患
• 腫瘍学

第10章 ブランドジェネリック市場：流通チャネル別

• オフライン
• オンライン

第11章 南北アメリカのブランドジェネリック市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のブランドジェネリック市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのブランドジェネリック市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • VyvanseジェネリックがFDAに承認
  • 製薬連盟とジェネリック医薬品協会がジェネリック医薬品の価格設定協定を更新
  • アムニール社、ザイレム（オキシバトナトリウム）の認可ジェネリックを発売、5つの複合ジェネリックのFDA承認を取得
  • アジャンタファーマは成長著しいアジア、アフリカ地域での事業拡大を目指す
  • ドクター・レディーズが国内市場でジェネリック医薬品事業に参入
  • サンファーマ、ファイザーの大ヒット抗がん剤のジェネリック版を発売
  • ゼンティバ、スペインのティロメッドから主要製品の買収を完了
  • シプラ社、便秘解消のための無糖経口乳剤下剤「イージーラックス L」を発売
  • プロキャップス・グループ、アドベント・インターナショナルからグルポ・ソマールを買収

第15章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. BRANDED GENERICS MARKET RESEARCH PROCESS
• FIGURE 2. BRANDED GENERICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. BRANDED GENERICS MARKET DYNAMICS
• FIGURE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 20. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 26. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BRANDED GENERICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL BRANDED GENERICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 79. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 80. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 85. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 86. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 87. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 88. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 89. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 90. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 91. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 92. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 93. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 94. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 95. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 96. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 97. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 98. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 99. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 100. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 101. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 102. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 103. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 104. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 105. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 106. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 107. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 108. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 109. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 110. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 111. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 112. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 113. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 114. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 115. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 116. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 117. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 118. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 119. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 120. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 121. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 122. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 123. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 124. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 125. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 126. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 127. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 128. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 129. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 130. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 131. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 132. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 133. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 134. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 135. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 136. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 137. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 138. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 139. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 140. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 141. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 142. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 144. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 145. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 146. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 148. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 149. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 150. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 152. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 154. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 155. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 156. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 157. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 158. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 159. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 160. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 161. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 162. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 163. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 164. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 165. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 166. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 167. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 168. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 169. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 170. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 171. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 172. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 173. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 174. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 175. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 176. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 177. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 178. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 179. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 180. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 181. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 182. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 183. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 184. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 185. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 186. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 187. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 188. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 189. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 190. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 191. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 192. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 193. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 194. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 195. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 196. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 197. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 198. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 199. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 200. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 201. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 202. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 203. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 204. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 205. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 206. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 207. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 208. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 209. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 210. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 211. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 212. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 213. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 214. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 215. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 216. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 217. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 218. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 219. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 220. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 221. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 222. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 223. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 224. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 225. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 226. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 227. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 228. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 229. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 230. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 231. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 232. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 233. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 234. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 235. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 236. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 237. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 238. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 239. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 240. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 241. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 242. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 243. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 244. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 245. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 246. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 247. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 248. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 249. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 250. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 251. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 252. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 253. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 254. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 255. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 256. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 257. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 258. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 259. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 260. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 261. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 262. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 263. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 264. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 265. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 266. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 267. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 268. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 269. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 270. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 271. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 272. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 273. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 274. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 275. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 276. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 277. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 278. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 279. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 280. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 281. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 282. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 283. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 284. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 285. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 286. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 287. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 288. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 289. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 290. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 291. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 292. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 293. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 294. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 295. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 296. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 297. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 298. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 299. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 300. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 301. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 302. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 303. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 304. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 306. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 307. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 308. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 309. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 310. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 311. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 312. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 313. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 314. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 315. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 316. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 317. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 318. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 319. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 320. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 321. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 322. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 323. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 324. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 325. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 326. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 327. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 328. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 329. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 330. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 331. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 332. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 333. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 334. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 335. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 336. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 337. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 338. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 339. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 340. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 341. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 342. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 343. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 344. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 345. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 346. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 347. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
• TABLE 348. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
• TABLE 349. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 350. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 351. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
• TABLE 352. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
• TABLE 353. FRANCE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTR

[194 Pages Report] The Branded Generics Market size was estimated at USD 432.30 billion in 2023 and expected to reach USD 494.29 billion in 2024, at a CAGR 14.66% to reach USD 1,126.43 billion by 2030.

Branded generic drugs refer to medications that are bioequivalent to the original innovator drug and are distributed under a different brand name by another company after patent expiration. These drugs are formulated using the same active pharmaceutical ingredients (APIs) as the innovator product and must meet similar regulatory requirements for manufacturing processes, safety profiles, and efficacy standards. However, branded generics may exhibit subtle differences in terms of excipients, packaging materials, or manufacturing techniques compared to their innovator counterparts. Increasing consumer awareness about accessible treatment options, rising healthcare expenditure, and increasing patent expirations on blockbuster drugs drive the growth of the branded generics market. However, stringent regulatory requirements for drug approval and quality control and price erosion resulting from intense competition among manufacturers may hinder market growth. Nevertheless, advancements in pharmaceutical research enabling the development of bioequivalent products create lucrative opportunities for the growth of the branded generics market.

Product: Significant adoption of value-added branded generics due to their additional advantages

Ttrade-named generics are the pharmaceutical product that combines the trusted efficacy of an established generic drug with the recognition and reputation of a well-known brand name. These products offer the benefits of both generic and branded medicines, with high quality at an affordable price. Pharmaceutical manufacturers commonly use trade-named generics to penetrate competitive markets, providing patients and healthcare professionals with cost-effective alternatives that maintain trust in safety, effectiveness, and reliability. Value-added offerings represent a distinct category that differentiates itself from standard formulations by bringing additional benefits to the consumer. These value-added products may combine multiple active ingredients for enhanced therapeutic effects or adopt innovative dosage forms for improved convenience, such as extended-release formulations or easy-to-swallow tablets. In some cases, value-added trade-named generics can also include drugs reformulated to reduce side effects or improve patient adherence, such as Benitek A (Olmesatran in combination with Amlodipine), Nifedical (nifedipine), and Digitek (digoxin).

Drug Type: High usage of anti-hypertensive for treating high blood pressure

Alkylating agents are a class of drugs primarily used in cancer treatment, and they work by inhibiting DNA replication restricting the growth and multiplication of cancer cells, such as cyclophosphamide, melphalan, and cisplatin. Anti-depressant medications are used to treat various forms of depression and anxiety disorders as they restore the balance of neurotransmitters within the brain, particularly serotonin, norepinephrine, and dopamine, and commonly prescribed anti-depressants include fluoxetine, venlafaxine, and amitriptyline. Anti-epileptic drugs (AEDs) are medications designed to prevent or control epileptic seizures in individuals diagnosed with epilepsy. Anti-hypertensive medications lower blood pressure in individuals with hypertension, reducing the risk of heart disease, stroke, and other complications. Antipsychotic medications are primarily used to manage symptoms of psychotic diseases such as bipolar disorder and schizophrenia. Antimetabolites are a group of chemotherapeutic agents that interfere with cellular metabolism and DNA synthesis in cancer cells while they mimic essential building blocks for DNA replication or inhibit critical enzymes involved in these processes. Hormone-based medications are used in various medical conditions, including hormone imbalances, endocrine disorders, and certain cancers. Lipid-lowering medications are designed to reduce elevated levels of triglyceride and cholesterol in the blood, lowering the chance of cardiovascular disorders such as heart attacks.

Route of Administration: Wide adoption of oral route due to their longer duration of action

The oral route is the most common and preferred method of drug administration due to its convenience, ease of use, and non-invasive nature. Branded generic medications in forms such as tablets, capsules, or liquids are taken orally by the patient. Additionally, they provide higher patient compliance as they do not require specialized equipment or healthcare professional oversight for administration. Parenteral administration involves delivering drugs directly into the bloodstream through means that bypass the digestive system. This route includes subcutaneous (SC), intramuscular (IM), and intravenous (IV) injections and infusions. This route is particularly beneficial when treating conditions requiring quick relief or if a drug has poor oral bioavailability. Additionally, it is generally more expensive than oral administration due to specialized equipment and sterile preparation requirements. Topical administration involves applying branded generic medications directly onto the skin or mucosal surfaces, such as creams, gels, ointments, or transdermal patches. This route allows localized drug delivery to the target site while minimizing systemic absorption and potential side effects. Advantages of topical administration include reduced risk of adverse reactions compared to systemic routes and improved patient compliance due to ease of use. However, challenges associated with topical drug delivery include variability in drug penetration through the skin barrier and the potential for irritation at the application site.

Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases

Branded generics are crucial in providing options for analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids. Branded generics offer cost-effective alternatives for cardiovascular diseases such as managing hypertension, hyperlipidemia, heart failure, and arrhythmias. Skin conditions such as acne, fungal infections, eczema, and psoriasis are widespread concerns among patients globally, and branded generics provide affordable access to dermatological treatments, including corticosteroids, retinoids, and antifungal agents. Gastrointestinal diseases such as inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS) require long-term management with medications that are fulfilled by branded generics that offer cost-effective therapies, including proton-pump inhibitors (PPIs), H2 receptor antagonists, and antispasmodics. Neurological disorders such as epilepsy, Parkinson's disease, multiple sclerosis, and migraines demand effective treatments at affordable prices, and branded generics help bridge this gap with anti-epileptic drugs (AEDs), dopaminergic agents, and monoclonal antibodies. Branded generics provide cost-effective alternatives for chemotherapy drugs, hormone therapies, immunotherapies, and tyrosine kinase inhibitors (TKIs) for cancer treatment, as they are perceived as unattainable due to the high costs associated with innovative therapies and targeted agents. Generic versions of Celebrex (celecoxib) capsules, Vascepa (icosapent ethyl) capsules, Jublia (efinaconazole) topical solution, Asacol HD (mesalamine) tablets, Abraxane (nab-paclitaxel), Ampyra (dalfampridine) extended-release tablets are available for treating several diseases.

Distribution Channel: Evolving online distribution channels for branded generics

The offline distribution channel for branded generics remains the first preference for patients seeking medications, primarily due to ease of access and real-time consultation with healthcare professionals. Hospital pharmacies play a vital role in providing quality healthcare by ensuring patients have access to affordable medications during treatment. Hospital pharmacies increasingly favor branded generics as they balance affordability and quality assurance. These drugs are manufactured following strict guidelines and maintain a high efficacy comparable to their patented counterparts. Retail pharmacies serve as a primary source of medications among the general public and create an enormous potential for branded generics as consumers seek cost-effective alternatives without compromising on quality or efficacy. The rapid advancement of digital technologies has paved the way for online pharmacies and eCommerce platforms to emerge as significant players in the pharmaceutical distribution landscape. Branded generics have observed substantial growth in this space due to the convenience and cost savings these online channels provide due to its accessibility of detailed product information, competitive pricing, and reliable delivery services that have led consumers to prefer purchasing their medications online.

Regional Insights

In the Americas region, the branded generics market has a lucrative landscape due to its robust healthcare infrastructure and high per capita spending on pharmaceuticals. The government's initiatives to increase awareness about generic drugs have led to promising growth prospects for branded generics. Additionally, the investment in R&D by leading pharmaceutical companies has resulted in new product approvals and innovative therapeutics entering this market space. The European Union showcases a diverse landscape within the branded generics sector. There is considerable demand for cost-effective treatment options with increasing healthcare expenditure across EU countries and favorable pricing policies for generic medicines by national governments. Major players are investing heavily in research activities to develop novel drugs while maintaining competitiveness against low-cost alternatives from emerging markets. The Middle East and Africa offer notable potential for growth in the branded generics market as the government initiatives aimed at improving healthcare infrastructure and affordability of medicines are driving factors contributing to expanding market opportunities. The Asia-Pacific showcases immense potential for branded generics development owing to the rising research and development, supportive government initiatives, increasing demand for trade generics, and surging collaborations among international players to develop innovative therapies catering to global needs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Branded Generics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Branded Generics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Branded Generics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ajanta Pharma Ltd., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Apotex Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Aurobindo Pharma Limited, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International PLC, Eris Lifesciences Limited, Eva Pharma, Fresenius Kabi AG, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Lupin Limited, Micro Labs Limited, Nichi-Iko Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH by Novartis AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., and Zentiva Group, a.s..

Market Segmentation & Coverage

This research report categorizes the Branded Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Trade Named Generics
  • Value-Added

• Drug Type
  • Alkylating Agents
  • Anti-depressants
  • Anti-epileptics
  • Anti-hypertensive
  • Anti-psychotics
  • Antimetabolites
  • Hormones
  • Lipid Lowering Drugs

• Route of Administration
  • Oral
  • Parenteral
  • Topical

• Indication
  • Acute & Chronic Pain
  • Cardiovascular Diseases
  • Dermatological Diseases
  • Gastrointestinal Diseases
  • Neurological Diseases
  • Oncology

• Distribution Channel
  • Offline
    • Hospital Pharmacy
    • Retail Pharmacy

• Online

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Branded Generics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Branded Generics Market?

3. What are the technology trends and regulatory frameworks in the Branded Generics Market?

4. What is the market share of the leading vendors in the Branded Generics Market?

5. Which modes and strategic moves are suitable for entering the Branded Generics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of chronic diseases necessitating the use of generic medications
    • 5.1.1.2. Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with quality variations in branded generic medications
  • 5.1.3. Opportunities
    • 5.1.3.1. Novel bioequivalence studies and efforts by market players to expand branded generics business
  • 5.1.4. Challenges
    • 5.1.4.1. Litigation issues and issues related to price erosion of innovator drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Significant adoption of value-added branded generics due to their additional advantages
  • 5.2.2. Drug Type: High usage of anti-hypertensive for treating high blood pressure
  • 5.2.3. Route of Administration: Wide adoption of oral route due to their longer duration of action
  • 5.2.4. Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
  • 5.2.5. Distribution Channel: Evolving online distribution channels for branded generics
• 5.3. Market Trend Analysis
  • 5.3.1. Availability of well-structured standards for branded generics in the Americas
  • 5.3.2. Supportive government initiatives and growing need for affordable branded generic drugs in the Asia-Pacific region
  • 5.3.3. Presence of well-established pharmaceutical companies emphasizing on expanding geographical reach of branded generics in the EMEA region
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework Analysis

6. Branded Generics Market, by Product

• 6.1. Introduction
• 6.2. Trade Named Generics
• 6.3. Value-Added

7. Branded Generics Market, by Drug Type

• 7.1. Introduction
• 7.2. Alkylating Agents
• 7.3. Anti-depressants
• 7.4. Anti-epileptics
• 7.5. Anti-hypertensive
• 7.6. Anti-psychotics
• 7.7. Antimetabolites
• 7.8. Hormones
• 7.9. Lipid Lowering Drugs

8. Branded Generics Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral
• 8.4. Topical

9. Branded Generics Market, by Indication

• 9.1. Introduction
• 9.2. Acute & Chronic Pain
• 9.3. Cardiovascular Diseases
• 9.4. Dermatological Diseases
• 9.5. Gastrointestinal Diseases
• 9.6. Neurological Diseases
• 9.7. Oncology

10. Branded Generics Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Offline
• 10.3. Online

11. Americas Branded Generics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Branded Generics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Branded Generics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Vyvanse Generics Approved by FDA
  • 14.3.2. Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement
  • 14.3.3. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
  • 14.3.4. Ajanta Pharma looks to expand ops in high-growth Asian, African geographies
  • 14.3.5. Dr Reddy's Enters Trade Generics Business In Domestic Market
  • 14.3.6. Sun Pharma Launches Generic Version of Pfizer's Blockbuster Cancer Drug
  • 14.3.7. Zentiva Completes Major Product Acquisition From Tillomed Spain
  • 14.3.8. Cipla Launches 'Easylax L',A Sugar-Free Oral Emulsion Laxative For Constipation Relief
  • 14.3.9. Procaps Group to Acquire Grupo Somar from Advent International

15. Competitive Portfolio

• 15.1. Key Company Profiles
• 15.2. Key Product Portfolio